An Open-Label, Phase II Study to Evaluate SCB01A in Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer Who Have Received Platinum-Based Treatment

Trial Profile

An Open-Label, Phase II Study to Evaluate SCB01A in Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer Who Have Received Platinum-Based Treatment

Discontinued
Phase of Trial: Phase II

Latest Information Update: 25 Oct 2017

At a glance

  • Drugs SB 01 (Primary)
  • Indications Head and neck cancer
  • Focus Therapeutic Use
  • Sponsors SynCore Biotechnology
  • Most Recent Events

    • 18 Oct 2017 Planned End Date changed from 1 Oct 2017 to 1 Dec 2017.
    • 18 Oct 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Dec 2017.
    • 18 Oct 2017 Status changed from recruiting to discontinued.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top